{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tacrolimus+%28Arm+A%29", "query": { "intervention": "Tacrolimus (Arm A)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 123, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tacrolimus+%28Arm+A%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T18:03:11.086Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06552169", "title": "REgulatory T Cell Therapy to Achieve Immunosuppression REduction", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Arm 1: SOC (mTOR + CNI)", "type": "DRUG" }, { "name": "Arm 2A: TRACT/MONO mTOR", "type": "BIOLOGICAL" }, { "name": "Arm 2B: TRACT/MONO CNI", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Singulera Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 34, "start_date": "2025-06-13", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-09-24T18:03:11.086Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06552169" }, { "nct_id": "NCT01680861", "title": "Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Transplant; Failure, Kidney" ], "interventions": [ { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Enteric Coated Mycophenolate Sodium (EC-MPS)", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gaetano Ciancio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 32, "start_date": "2012-11", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-09-24T18:03:11.086Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01680861" }, { "nct_id": "NCT01650545", "title": "Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Disorder Related to Lung Transplantation", "Bronchiolitis Obliterans", "Decreased Immunologic Activity", "Chronic Rejection of Lung Transplant" ], "interventions": [ { "name": "Liposomal aerosol cyclosporine", "type": "DRUG" }, { "name": "standard immune suppression, oral", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2012-07", "completion_date": "2019-11", "has_results": true, "last_update_posted_date": "2023-06-01", "last_synced_at": "2026-09-24T18:03:11.086Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01650545" }, { "nct_id": "NCT02446431", "title": "Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Miller Children's & Women's Hospital Long Beach", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "31 Years", "sex": "ALL", "summary": "12 Months to 31 Years" }, "enrollment_count": 20, "start_date": "2014-07", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2015-05-18", "last_synced_at": "2026-09-24T18:03:11.086Z", "location_count": 2, "location_summary": "Long Beach, California • Orange, California", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02446431" }, { "nct_id": "NCT01935128", "title": "Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Renal Transplant" ], "interventions": [ { "name": "Arm 1 Everolimus/Reduced dose tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Toledo Health Science Campus", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2013-07-03", "completion_date": "2020-07", "has_results": true, "last_update_posted_date": "2022-05-26", "last_synced_at": "2026-09-24T18:03:11.086Z", "location_count": 1, "location_summary": "Toledo, Ohio", "locations": [ { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01935128" }, { "nct_id": "NCT00448201", "title": "Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 71, "start_date": "2011-01-07", "completion_date": "2012-05-23", "has_results": true, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-09-24T18:03:11.086Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00448201" }, { "nct_id": "NCT02213068", "title": "Belatacept 3 Month Post Transplant Conversion Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Transplant; Failure, Kidney", "EBV" ], "interventions": [ { "name": "belatacept", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "MPA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lorenzo Gallon", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2014-07", "completion_date": "2020-09", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-09-24T18:03:11.086Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02213068" }, { "nct_id": "NCT00089011", "title": "Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Myelodysplastic Syndromes", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Chronic Phase Chronic Myelogenous Leukemia", "Contiguous Stage II Adult Burkitt Lymphoma", "Contiguous Stage II Adult Diffuse Large Cell Lymphoma", "Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Contiguous Stage II Adult Lymphoblastic Lymphoma", "Contiguous Stage II Grade 1 Follicular Lymphoma", "Contiguous Stage II Grade 2 Follicular Lymphoma", "Contiguous Stage II Grade 3 Follicular Lymphoma", "Contiguous Stage II Mantle Cell Lymphoma", "Contiguous Stage II Marginal Zone Lymphoma", "Contiguous Stage II Small Lymphocytic Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "de Novo Myelodysplastic Syndromes", "Essential Thrombocythemia", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Polycythemia Vera", "Post-transplant Lymphoproliferative Disorder", "Previously Treated Myelodysplastic Syndromes", "Primary Myelofibrosis", "Prolymphocytic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage I Adult Burkitt Lymphoma", "Stage I Adult Diffuse Large Cell Lymphoma", "Stage I Adult Diffuse Mixed Cell Lymphoma", "Stage I Adult Diffuse Small Cleaved Cell Lymphoma", "Stage I Adult Immunoblastic Large Cell Lymphoma", "Stage I Adult Lymphoblastic Lymphoma", "Stage I Adult T-cell Leukemia/Lymphoma", "Stage I Childhood Anaplastic Large Cell Lymphoma", "Stage I Childhood Large Cell Lymphoma", "Stage I Childhood Lymphoblastic Lymphoma", "Stage I Childhood Small Noncleaved Cell Lymphoma", "Stage I Chronic Lymphocytic Leukemia", "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage I Grade 1 Follicular Lymphoma", "Stage I Grade 2 Follicular Lymphoma", "Stage I Grade 3 Follicular Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage I Marginal Zone Lymphoma", "Stage I Multiple Myeloma", "Stage I Small Lymphocytic Lymphoma", "Stage IA Mycosis Fungoides/Sezary Syndrome", "Stage IB Mycosis Fungoides/Sezary Syndrome", "Stage II Adult T-cell Leukemia/Lymphoma", "Stage II Childhood Anaplastic Large Cell Lymphoma", "Stage II Childhood Large Cell Lymphoma", "Stage II Childhood Lymphoblastic Lymphoma", "Stage II Childhood Small Noncleaved Cell Lymphoma", "Stage II Chronic Lymphocytic Leukemia", "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage II Multiple Myeloma", "Stage IIA Mycosis Fungoides/Sezary Syndrome", "Stage IIB Mycosis Fungoides/Sezary Syndrome", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-cell Leukemia/Lymphoma", "Stage III Childhood Anaplastic Large Cell Lymphoma", "Stage III Childhood Large Cell Lymphoma", "Stage III Childhood Lymphoblastic Lymphoma", "Stage III Childhood Small Noncleaved Cell Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Stage III Small Lymphocytic Lymphoma", "Stage IIIA Mycosis Fungoides/Sezary Syndrome", "Stage IIIB Mycosis Fungoides/Sezary Syndrome", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Childhood Anaplastic Large Cell Lymphoma", "Stage IV Childhood Large Cell Lymphoma", "Stage IV Childhood Lymphoblastic Lymphoma", "Stage IV Childhood Small Noncleaved Cell Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Small Lymphocytic Lymphoma", "Stage IVA Mycosis Fungoides/Sezary Syndrome", "Stage IVB Mycosis Fungoides/Sezary Syndrome", "Testicular Lymphoma", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia", "Untreated Childhood Acute Lymphoblastic Leukemia", "Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "74 Years", "sex": "ALL", "summary": "Up to 74 Years" }, "enrollment_count": 150, "start_date": "2004-04", "completion_date": "2018-07", "has_results": true, "last_update_posted_date": "2020-01-29", "last_synced_at": "2026-09-24T18:03:11.086Z", "location_count": 4, "location_summary": "Salt Lake City, Utah • Seattle, Washington", "locations": [ { "city": "Salt Lake City", "state": "Utah" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089011" }, { "nct_id": "NCT01729494", "title": "Belatacept Early Steroid Withdrawal Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Renal Transplantation" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "rabbit antithymocyte globulin", "type": "DRUG" }, { "name": "Belatacept", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "early cessation of steroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2012-09", "completion_date": "2019-12", "has_results": true, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-24T18:03:11.086Z", "location_count": 8, "location_summary": "San Francisco, California • Denver, Colorado • Tampa, Florida + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01729494" }, { "nct_id": "NCT03320642", "title": "GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Calcineurin inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2018-02-27", "completion_date": "2022-02-17", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-09-24T18:03:11.086Z", "location_count": 9, "location_summary": "Aurora, Colorado • Atlanta, Georgia • Maywood, Illinois + 6 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03320642" } ] }